406 related articles for article (PubMed ID: 28895028)
1. Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study.
Khan Q; Ismail M; Haider I; Khan F
Int J Clin Pharm; 2017 Dec; 39(6):1256-1264. PubMed ID: 28895028
[TBL] [Abstract][Full Text] [Related]
2. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study.
Khan Q; Ismail M; Khan S
BMC Pharmacol Toxicol; 2017 Dec; 18(1):75. PubMed ID: 29191244
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients.
Khan Q; Ismail M; Haider I; Ali Z
J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):109-115. PubMed ID: 29458991
[TBL] [Abstract][Full Text] [Related]
4. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
Das B; Rawat VS; Ramasubbu SK; Kumar B
Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units.
Khan Q; Ismail M; Haider I
Postgrad Med; 2018 Nov; 130(8):660-665. PubMed ID: 30145917
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic Drug-Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients.
Hefner G; Hahn M; Hiemke C; Toto S; Wolff J; Roll SC; Klimke A
J Neural Transm (Vienna); 2021 Feb; 128(2):243-252. PubMed ID: 33417009
[TBL] [Abstract][Full Text] [Related]
7. QT interval prolongation in hospitalized patients on cardiology wards: a prospective observational study.
Khan Q; Ismail M; Haider I; Haq IU; Noor S
Eur J Clin Pharmacol; 2017 Nov; 73(11):1511-1518. PubMed ID: 28803378
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People.
Franchi C; Ardoino I; Rossio R; Nobili A; Biganzoli EM; Marengoni A; Marcucci M; Pasina L; Tettamanti M; Corrao S; Mannucci PM;
Drugs Aging; 2016 Jan; 33(1):53-61. PubMed ID: 26693921
[TBL] [Abstract][Full Text] [Related]
9. Investigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data.
Meid AD; von Medem A; Heider D; Adler JB; Günster C; Seidling HM; Quinzler R; König HH; Haefeli WE
Drug Saf; 2017 Feb; 40(2):133-144. PubMed ID: 27896662
[TBL] [Abstract][Full Text] [Related]
10. Leading 20 drug-drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients.
Das B; Ramasubbu SK; Agnihotri A; Kumar B; Rawat VS
Ther Adv Cardiovasc Dis; 2021; 15():17539447211058892. PubMed ID: 34841978
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of QT-Prolonging Drug-Drug Interactions in Psychiatry: A Systematic Review and Meta Analysis.
Ramasubbu SK; Mishra A; Mandal S
J Pharm Pract; 2024 Feb; 37(1):162-168. PubMed ID: 35968552
[No Abstract] [Full Text] [Related]
12. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update.
Beach SR; Celano CM; Sugrue AM; Adams C; Ackerman MJ; Noseworthy PA; Huffman JC
Psychosomatics; 2018; 59(2):105-122. PubMed ID: 29275963
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.
Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ
Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851
[TBL] [Abstract][Full Text] [Related]
14. Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation.
Niedrig D; Maechler S; Hoppe L; Corti N; Kovari H; Russmann S
Eur J Clin Pharmacol; 2016 Jul; 72(7):859-67. PubMed ID: 27023463
[TBL] [Abstract][Full Text] [Related]
15. Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium.
Vandael E; Marynissen T; Reyntens J; Spriet I; Vandenberghe J; Willems R; Foulon V
Int J Clin Pharm; 2014 Aug; 36(4):757-65. PubMed ID: 24805801
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia.
Moreno-Gutiérrez PA; Gaviria-Mendoza A; Cañón MM; Machado-Alba JE
Br J Clin Pharmacol; 2016 Aug; 82(2):504-11. PubMed ID: 27060989
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of QTc interval prolongation and its associated risk factors among psychiatric patients: a prospective observational study.
Ali Z; Ismail M; Nazar Z; Khan F; Khan Q; Noor S
BMC Psychiatry; 2020 Jun; 20(1):277. PubMed ID: 32493330
[TBL] [Abstract][Full Text] [Related]
18. [Drug-drug interactions with risk of QT-prolongation. A epidemiological study in Belgian community pharmacies].
Vandael E; De WuLf I; Foulon V
J Pharm Belg; 2016 Dec; (4):14-23. PubMed ID: 30281244
[TBL] [Abstract][Full Text] [Related]
19. QTc Prolongation Associated With Psychiatric Medications: A Retrospective Cross-Sectional Study of Adult Inpatients.
Shao W; Ayub S; Drutel R; Heise WC; Gerkin R
J Clin Psychopharmacol; 2019; 39(1):72-77. PubMed ID: 30531476
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?
Romero J; Baldinger SH; Goodman-Meza D; Engstrom K; Valencia CR; Golive A; Medrano F; Rangasamy S; Makkiya M; Fisher JD; Gross J; Krumerman A; Kim S; Garcia MJ; Di Biase L; Ferrick KJ
J Interv Card Electrophysiol; 2016 Jan; 45(1):37-45. PubMed ID: 26589717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
